Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott

For a retirement investor deciding between Medtronic (NYSE:MDT | MDT Price Prediction) and Abbott Laboratories (NYSE:ABT) today, the question is blunt: which medical device dividend deserves the retirement dollar right now? One pays more today. The other has raised longer and compounded harder. That is the trade, and it deserves a direct answer rather than a split decision.

Dimension 1: The Dividend Itself

Medtronic yields 3.11% on a forward annualized payout of $2.88, backed by 49 consecutive years of dividend increases and a most recent bump from $0.71 to $0.72 quarterly. Abbott yields 2.4% on $2.52 annualized, but carries 54 consecutive years of increases as an S&P 500 Dividend Aristocrat, with a fresher lift from $0.59 to $0.63.

Medtronic generated $7.33 billion in operating cash flow in FY26 against a $3.64 billion dividend payout. Abbott returned $2.1 billion to shareholders in Q2 2026 alone via dividends and buybacks. Abbott has the longer streak and the faster recent raise (the kind of 50-plus-year runway that put it in our free Dividend Kings guide, where we ranked ten of them by today’s valuation). Medtronic delivers materially more income per dollar invested today. Winner for income now: Medtronic.

Dimension 2: The Underlying Business

Abbott is the broader franchise: medical devices, diagnostics (now supercharged by the $21 billion Exact Sciences acquisition completed March 23, 2026), established pharmaceuticals, and nutrition. Diversification cushions any one reimbursement or regulatory shock. Q2 2026 revenue reached $12.59 billion (+13.02% YoY), with medical devices up 9.0% and continuous glucose monitors clearing $2 billion in quarterly sales.

Medtronic is a purer device play, and the growth engine has re-ignited. Q1 FY27 revenue hit $9.76 billion (+13.7% YoY), with the Cardiovascular Portfolio up 18.9% organically and Cardiac Ablation Solutions up 88%. Management raised FY27 organic revenue guidance to 7.25%–7.75%, edging Abbott’s reaffirmed 6.5%–7.5% comparable sales range.

Both face hospital-spending cycles and reimbursement risk (Abbott flagged Structural Heart U.S. sales down 9.8%), but Medtronic’s top-line acceleration and the planned Diabetes business separation are the crisper near-term story. Medtronic is the winner on growth trajectory, but Abbot wins whe it comes to quality and durability.

Dimension 3: What You Are Paying

Medtronic trades at a trailing P/E of 23 and a forward P/E of 15, with shares at $90.98, down 3.69% year to date and off the 52-week high of $103.76. Abbott commands a trailing P/E of 33 and forward P/E of 17, at $101.93 after a 17.13% YTD drawdown from a 52-week high of $134.38. Both are cheaper than they were nine months ago. Medtronic is cheaper on every meaningful multiple. Winner: Medtronic.

Verdict

For the retirement-focused income investor buying today, Medtronic wins. You collect a 3.11% yield versus 2.4%, pay a materially lower earnings multiple, and get accelerating organic growth into a diabetes-separation catalyst. That is income now, at a discount, with a re-rating optionality.

Abbott is the better call for a different reader: the retiree still in accumulation mode with a decade-plus horizon, who wants Aristocrat pedigree, a diversified moat, and Exact Sciences-fueled compounding. Abbott’s 202.76% ten-year return versus Medtronic’s 39.83% is the fair argument for the loser here, and it is not a small one.

One thing to watch that flips the verdict: Medtronic’s EPS beat streak. Break the five-quarter streak of beats, or slip on the FY27 guide of $5.94–$6.00, and the yield advantage stops compensating for the execution risk. Then Abbott’s quality premium earns its keep.

Contact [email protected] for any questions or corrections.